Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy

Laryngoscope

Volumn 119, Issue 4, 2009, Pages 665-674

  Saito, Koichiro ^a   Khan, Khurram ^a   Sosnowski, Barbara ^b   Li, Daqing ^a   O'malley Jr , Bert W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Tissue Repair Company   (United States)

Author keywords

Adenoviral gene therapy; Antiangiogenesis; Head and neck ranrdr; HSV tk; Retargeting

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 2 IMMUNOGLOBULIN F(AB) FRAGMENT CONJUGATED BETA GALACTOSIDASE; FIBROBLAST GROWTH FACTOR 2 IMMUNOGLOBULIN F(AB) FRAGMENT CONJUGATED THYMIDINE KINASE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GANCICLOVIR; IMMUNOGLOBULIN F(AB) FRAGMENT; MESSENGER RNA; THYMIDINE KINASE; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SUICIDE GENE THERAPY; TRANSGENE; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; ENZYMOLOGY; GENE THERAPY; GENE VECTOR; GENETICS; HEAD AND NECK TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); RANDOMIZATION; TISSUE DISTRIBUTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; RECOMBINANT PROTEINS; SIMPLEXVIRUS; THYMIDINE KINASE; TISSUE DISTRIBUTION; TRANSGENES;

EID: 65249108644     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20127     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. O'Malley BW Jr, Chen SH, Schwartz MR, Woo SL. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995; 55:1080-1085.
3. Nemunaitis J., Khuri F., Ganly I., et al. Phase II trial of intratumoral administration of ONYX-015, a replicationselective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19:289-298.
4. Moon C., Oh Y., Roth JA. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res 2003; 9:5055-5067.
5. Andrade-Rozental AF, Rozental R., Hopperstad MG, Wu JK, Vrionis FD, Spray DC. Gap junctions: the "kiss of death" and the "kiss of life". Brain Res Brain Res Rev 2000; 32: 308-315.
6. Li D., Duan L., Freimuth P., O'Malley BW Jr. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999; 5:4175-4181.
7. Huard J., Lochmuller H., Acsadi G., Jani A., Massie B., Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995; 2:107-115.
8. Gao GP, Yang Y., Wilson JM. Biology of adenovirus vectors with El and E4 deletions for liver-directed gene therapy. J Virol 1996; 70:8934-8943.
9. Doukas J., Hoganson DK, Ong M., et al. Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. FASEB J 1999; 13:1459-1466.
10. Gu DL, Gonzalez AM, Printz MA, et al. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res 1999; 59:2608-2614.
11. Hoganson DK, Sosnowski BA, Pierce GF, Doukas J. Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. Mol Ther 2001; 3:105-112.
12. Kleeff J., Fukahi K., Lopez ME, et al. Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Ther 2002; 9:522-532.
13. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16:159-178.
14. Bikfalvi A., Klein S., Pintucci G., Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997; 18: 26-45.
15. Galzie Z., Kinsella AR, Smith JA. Fibroblast growth factors and their receptors. Biochem Cell Biol 1997; 75:669-685.
16. Grose R., Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16: 179-186.
17. Dellacono FR, Spiro J., Eisma R., Kreutzer D. Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells. Am J Surg 1997; 174:540-544.
18. Wakulich C., Jackson-Boeters L., Daley TD, Wysocki GP. Immunohistochemical localization of growth factors fibroblast growth factor-1 and fibroblast growth factor-2 and receptors fibroblast growth factor receptor-2 and fibroblast growth factor receptor-3 in normal oral epithelium, epithelial dysplasias, and squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 573-579.
19. Jaye M., Schlessinger J., Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta 1992; 1135: 185-199.
20. Rogers BE, Douglas JT, Ahlem C., Buchsbaum DJ, Frincke J., Curiel DT. Use of a novel cross-linking method to modify adenovirus tropism. Gene Ther 1997; 4:1387-1392.
21. Rancourt C., Rogers BE, Sosnowski BA, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998; 4: 2455-2461.
22. Reynolds P., Miller C., Goldman CK. Targeting adenovial infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells. Tumor Targeting 1998; 3:156-168.
23. Qin M., Escuadro B., Sharma S., Batra RK. Gene transfer mediated by native versus fibroblast growth factor-retargeted adenoviral vectors into lung cancer cells. Am J Respir Cell Mol Biol 2005; 32:211-217.
24. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
25. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003; 2:S127-S133.
26. Riedel F., Gotte K., Bergler W., Rojas W., Hormann K. Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer. Head Neck 2000; 22:183-189.
27. Martone T., Rosso P., Albera R., et al. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. Oral Oncol 2005; 41:147-155.
28. Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenoviral vectors. Mol Ther 2000; 1:391-405.
29. Palu G., Cavaggioni A., Calvi P., et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther 1999; 6:330-337.
30. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36: 169-180.
31. Mavria G., Harrington KJ, Marshall CJ, Porter CD. In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy. J Gene Med 2005; 7:263-275.
32. Griscelli F., Li H., Bennaceur-Griscelli A., et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998; 95: 6367-6372.
33. Calvo A., Feldman AL, Libutti SK, Green JE. Adenovirusmediated endostatin delivery results in inhibition of mammary gland tumor growth in C3 (1)/SV40 T-antigen transgenic mice. Cancer Res 2002; 62:3934-3938.